FDA Approves Zelsuvmi (berdazimer topical gel) for the Treatment of Molluscum Contagiosum
Ligand Pharmaceuticals Incorporated has announced that the U.S. Food and Drug Administration (FDA) has approved Zelsuvmi™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (MC) in adults and pediatric patients one year of age and older. The FDA approved Zelsuvmi as the first novel drug for the treatment of molluscum infections.
Zelsuvmi is the first and only topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician’s office, or other medical setting to treat this highly contagious viral skin infection.
Molluscum is a highly contagious viral skin infection characterized by skin-colored to red lesions with a central, umbilicated viral core. Approximately 6 million Americans, primarily children, are infected each year. However, up to 73% of children go untreated. Treating the lesions is critical to preventing the viral infection from spreading to other people or to other areas of the body.
Zelsuvmi is expected to be available in the United States in the second half of 2024.
